Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.

Developments in biological standardization

Volumn 88, Issue , 1996, Pages 257-264

  Kozak, R W ^a   Golker, C F ^a   Stadler, P ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; BIOLOGICAL PRODUCT;

ANIMAL; ARTICLE; BLOOD; CATTLE; CELL LINE; DISEASE TRANSMISSION; DRUG CONTAMINATION; DRUG INDUSTRY; HUMAN; ISOLATION AND PURIFICATION; LUNG; PRION; PRION DISEASE; RISK ASSESSMENT; STANDARD; VIROLOGY;

ANIMALS; APROTININ; BIOLOGICAL PRODUCTS; BLOOD; CATTLE; CELL LINE; DRUG CONTAMINATION; DRUG INDUSTRY; HUMANS; LUNG; PRION DISEASES; PRIONS; RISK ASSESSMENT;

EID: 0030333364     PISSN: 03015149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)